THE COMPANY
We bring working models, scientific leadership and proprietary development together around one ambition: making individual treatment response more predictable.
OUR PURPOSE
NUMEN exists to make individual response a stronger part of treatment development and future care. We are building the platform for that ambition, starting with a defined application, then extending through reusable technology.
Healing, made predictable.
WHY NUMEN
Our strength is the combination: existing technical capability, published scientific experience and company-held intellectual property, directed towards one platform.
Existing modelling capability gives NUMEN a technical starting point for platform and application development.
Digital biomarker and prognostic-modelling research within our scientific team. *1 *2
Relevant intellectual property is assigned to NUMEN under company agreements.
LEADERSHIP & ADVISORY
Founder & CEO
Martin combines a background in computer science, cybersecurity and quantitative algorithms with an Executive MBA in Business Engineering from the University of St.Gallen (HSG). As Founder & CEO, he brings this technical and business perspective to NUMEN. He is also a coauthor of the 2026 Digital Neuro Fingerprints perspective. *2
Chief Scientific Officer
Ioannis brings digital biomarker and prognostic-modelling expertise to his role as Chief Scientific Officer. His published work includes the 2020 empirical study of individualised prognosis in people at risk of dementia and the 2026 Digital Neuro Fingerprints perspective. At NUMEN, that experience informs the scientific direction of therapy-response research. *1 *2
2020 publication: Individualised prognosis in dementia research2026 publication: Digital Neuro Fingerprints
Scientific Advisor
Panagiotis brings computational bioscience and digital biomarker expertise to NUMEN’s scientific advisory. A coauthor of the 2020 dementia-prognosis study and the 2026 Digital Neuro Fingerprints perspective, he contributes experience at the intersection of biological questions, computational models and research evidence. *1 *2
2020 publication: Individualised prognosis in dementia research2026 publication: Digital Neuro Fingerprints
LONG-TERM PERSPECTIVE
The first application is not the limit of NUMEN. Our ambition is to build a family of therapy-specific models on a shared platform, then deepen the picture of individual response across time.
The individual remains more than the model.
CONNECT
We welcome conversations about research, strategic collaboration and long-term company development.